BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/14/2025 12:55:58 PM | Browse: 195 | Download: 517
 |
Received |
|
2025-03-24 07:07 |
|
Peer-Review Started |
|
2025-03-24 07:07 |
|
First Decision by Editorial Office Director |
|
2025-04-03 08:51 |
|
Return for Revision |
|
2025-04-03 08:51 |
|
Revised |
|
2025-04-17 07:31 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-05-30 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-05-30 06:57 |
|
Articles in Press |
|
2025-05-30 06:57 |
|
Edit the Manuscript by Language Editor |
|
2025-06-08 00:45 |
|
Typeset the Manuscript |
|
2025-07-01 00:17 |
|
Publish the Manuscript Online |
|
2025-07-14 12:55 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Targeting SHP2: Dual breakthroughs in colorectal cancer therapy–from signaling pathway modulation to immune microenvironment remodeling
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Pan Liu and Jia Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Zhejiang Provincial Natural Science Foundation for Youths |
QN25H160012 |
| Zhejiang Medical and Health Science and Technology Plan |
2023RC006 |
|
| Corresponding Author |
Jia Chen, Clinical Assistant Professor (Honorary), Pulmonary and Critical Care Medicine, Zhuji Central Hospital, Zhugong Road No.98, Zhuji 311800, Zhejiang Province, China. 13357530129@163.com |
| Key Words |
Colorectal cancer; Protein tyrosine phosphatase SHP2; Targeted therapy; PI3K/AKT pathway; Tumor microenvironment |
| Core Tip |
This paper summarizes the regulatory mechanisms of SHP2 in colorectal cancer (CRC) and emerging therapeutic strategies targeting SHP2. The findings demonstrated that SHP2 serves as a master oncogenic regulator in CRC pathogenesis by coordinating receptor tyrosine phosphatase-mediated signaling. Notably, SHP2 remodels the tumor immune microenvironment by modulating macrophage and T cell functions. Allosteric inhibitors of SHP2, which are characterized by high oral bioavailability and potent target specificity, are currently under evaluation in multicenter phase I/II trials. Although acquired resistance remains challenging, combination strategies, particularly immunotherapy-based treatments, demonstrated transformative potential, accelerating the transition of SHP2-targeted therapies and offering novel paradigms for personalized CRC treatment. |
| Publish Date |
2025-07-14 12:55 |
| Citation |
Liu P, Chen J. Targeting SHP2: Dual breakthroughs in colorectal cancer therapy–from signaling pathway modulation to immune microenvironment remodeling. World J Gastrointest Oncol 2025; 17(7): 107380 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i7/107380.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i7.107380 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
